Regulation of Type 1 Diabetes by NKT Cells

REFERENCES

• R. Tisch and H. McDevitt, Insulin-dependent diabetes mellitus, Cell, 85: 291–297, 1996.
   PubMed Web of Science ®Google Scholar
• M.A. Atkinson and G.S. Eisenbarth, Type 1 diabetes: New perspectives on disease pathogenesis and treatment, Lancet, 358: 221–229, 2001.
   PubMed Web of Science ®Google Scholar
• L.M. Maier and L.S. Wicker, Genetic susceptibility to type 1 diabetes, Curr. Opin. Immunol., 17: 601–608, 2005.
   PubMed Web of Science ®Google Scholar
• M.S. Anderson and J.A. Bluestone. The NOD mouse: A model of immune dysregulation, Annu. Rev. Immunol., 23: 447–485, 2005.
   PubMed Web of Science ®Google Scholar
• B.O. Roep, M. Atkinson, and M. von Herrath, Opinion: Satisfaction (not) guaranteed: Re-evaluating the use of animal models of type 1 diabetes, Nat. Rev. Immunol., 4: 989–997, 2004.
   PubMedGoogle Scholar
• J.D. Katz, B. Wang, K. Haskins, C. Benoist, and D. Mathis, Following a diabetogenic T cell from genesis through pathogenesis, Cell, 74: 1089–1100, 1993.
   PubMed Web of Science ®Google Scholar
• A. Gonzalez, I. Andre-Schmutz, C. Carnaud, D. Mathis, and C. Benoist, Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes, Nat. Immunol., 2: 1117–1125, 2001.
   Google Scholar
• R. Yasunami and J.F. Bach, Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice, Eur. J. Immunol., 18: 481–484, 1988.
   PubMed Web of Science ®Google Scholar
• A. Bendelac, M.N. Rivera, S.H. Park, and J.H. Roark, Mouse CD1-specific NK1 T cells: development, specificity, and function, Annu. Rev. Immunol., 15: 535–562, 1997.
   PubMed Web of Science ®Google Scholar
• M. Brigl and M.B. Brenner, CD1: Antigen presentation and T cell function, Annu. Rev. Immunol., 22: 817–890, 2004.
   PubMed Web of Science ®Google Scholar
• M. Kronenberg and L. Gapin, The unconventional lifestyle of NKT cells, Nat. Rev. Immunol., 2: 557–568, 2002.
   PubMed Web of Science ®Google Scholar
• S.B. Wilson and T.L. Delovitch, Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity, Nat. Rev. Immunol., 3: 211–222, 2003.
   PubMed Web of Science ®Google Scholar
• D.I. Godfrey and M. Kronenberg, Going both ways: Immune regulation via CD1d-dependent NKT cells, J. Clin. Invest., 114: 1379–1388, 2004.
   PubMed Web of Science ®Google Scholar
• J.M. Gombert, A. Herbelin, E. Tancrede-Bohin, M. Dy, C. Carnaud, and J.F. Bach, Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse, Eur. J. Immunol., 26: 2989–2998, 1996.
   PubMed Web of Science ®Google Scholar
• A.G. Baxter, S.J. Kinder, K.J. Hammond, R. Scollay, and D.I. Godfrey, Association between αβTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice, Diabetes, 46: 572–582, 1997.
   PubMed Web of Science ®Google Scholar
• M.J. Wagner, S. Hussain, M. Mehan, J.M. Verdi, and T.L. Delovitch, A defect in lineage fate decision during fetal thymic invariant NKT cell development may regulate susceptibility to type 1 diabetes, J. Immunol., 174: 6764–6771, 2005.
   Google Scholar
• A. Lehuen, O. Lantz, L. Beaudoin, V. Laloux, C. Carnaud, A. Bendelac, J.F. Bach, and R.C. Monteiro, Overexpression of natural killer T cells protects Vα14- Jα281 transgenic nonobese diabetic mice against diabetes, J. Exp. Med., 188: 1831–1839, 1998.
   PubMed Web of Science ®Google Scholar
• M. Falcone, B. Yeung, L. Tucker, E. Rodriguez, and N. Sarvetnick, A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus, J. Exp. Med., 190: 963–972, 1999.
   PubMed Web of Science ®Google Scholar
• K.J. Hammond, L.D. Poulton, L.J. Palmisano, P.A. Silveira, D.I. Godfrey, and A.G. Baxter, α/β-T cell receptor (TCR) + CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10, J. Exp. Med., 187: 1047–1056, 1998.
   PubMed Web of Science ®Google Scholar
• F.D. Shi, M. Flodstrom, B. Balasa, S.H. Kim, K. Van Gunst, J.L. Strominger, S.B. Wilson, and N. Sarvetnick, Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse, Proc. Natl. Acad. Sci. U.S.A., 98: 6777–6782, 2001.
   PubMed Web of Science ®Google Scholar
• B. Wang, Y.B. Geng, and C.R. Wang, CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes, J. Exp. Med., 194: 313–320, 2001.
   PubMed Web of Science ®Google Scholar
• Y.N. Naumov, K.S. Bahjat, R. Gausling, R. Abraham, M.A. Exley, Y. Koezuka, S.B. Balk, J.L. Strominger, M. Clare-Salzer, and S.B. Wilson, Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets, Proc. Natl. Acad. Sci. U. S. A., 98: 13838–13843, 2001.
   PubMed Web of Science ®Google Scholar
• C. Carnaud, J.M. Gombert, O. Donnars, H.J. Garchon, and A. Herbelin, Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex, J. Immunol., 166: 2404–2411, 2001.
   PubMedGoogle Scholar
• L.M. Esteban, T. Tsoutsman, M.A. Jordan, D. Roach, L.D. Poulton, A. Brooks, O.V. Naidenko, S. Sidobre, D.I. Godfrey, and A.G. Baxter, Genetic control of NKT cell numbers maps to major diabetes and lupus loci, J. Immunol., 171: 2873–2878, 2003.
   PubMedGoogle Scholar
• S. Sharif, G.A. Arreaza, P. Zucker, Q.S. Mi, J. Sondhi, O.V. Naidenko, M. Kronenberg, Y. Koezuka, T.L. Delovitch, J.M. Gombert, M. Leite-De-Moraes, C. Gouarin, R. Zhu, A. Hameg, T. Nakayama, M. Taniguchi, F. Lepault, A. Lehuen, J.F. Bach, and A. Herbelin, Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes, Nat. Med., 7: 1057–1062, 2001.
   PubMed Web of Science ®Google Scholar
• S. Hong, M.T. Wilson, I. Serizawa, L. Wu, N. Singh, O.V. Naidenko, T. Miura, T. Haba, D.C. Scherer, J. Wei, M. Kronenberg, Y. Koezuka, and L. Van Kaer, The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice, Nat. Med., 7: 1052–1056, 2001.
   PubMed Web of Science ®Google Scholar
• J.S. Bezbradica, A.K. Stanic, N. Matsuki, H. Bour-Jordan, J.A. Bluestone, J.W. Thomas, D. Unutmaz, L. Van Kaer, and S. Joyce, Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo, J. Immunol., 174: 4696–4705, 2005.
   PubMed Web of Science ®Google Scholar
• Q.S. Mi, D. Ly, P. Zucker, M. McGarry, and T.L. Delovitch, Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells, Diabetes, 53: 1303–1310, 2004.
   PubMed Web of Science ®Google Scholar
• Y. Yasunami, S. Kojo, H. Kitamura, A. Toyofuku, M. Satoh, M. Nakano, K. Nabeyama, Y. Nakamura, N. Matsuoka, S. Ikeda, M. Tanaka, J. Ono, N. Nagata, O. Ohara, and M. Taniguchi, Vα14 NK T cell-triggered IFN-gamma production by Gr-1 + CD11b + cells mediates early graft loss of syngeneic transplanted islets, J. Exp. Med., 202: 913–918, 2005.
   PubMedGoogle Scholar
• S. Oki, A. Chiba, T. Yamamura, and S. Miyake, The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells, J. Clin. Invest., 113: 1631–1640, 2004.
   PubMed Web of Science ®Google Scholar
• M. Mizuno, M. Masumura, C. Tomi, A. Chiba, S. Oki, T. Yamamura, and S. Miyake, Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice, J. Autoimmun., 23: 293–300, 2004.
   PubMed Web of Science ®Google Scholar
• M. Falcone, F. Facciotti, N. Ghidoli, P. Monti, S. Olivieri, L. Zaccagnino, E. Bonifacio, G. Casorati, F. Sanvito, and N. Sarvetnick, Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice, J. Immunol., 172: 5908–5916, 2004.
   PubMed Web of Science ®Google Scholar
• V. Laloux, L. Beaudoin, D. Jeske, C. Carnaud, and A. Lehuen, NK T Cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen, J. Immunol., 166: 3749–3756, 2001.
   PubMedGoogle Scholar
• J.A. Cain, J.A. Smith, J.K. Ondr, B. Wang, and J.D. Katz, NKT cells and IFN-γ establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse, J. Immunol., 176: 1645–1654, 2006.
   PubMed Web of Science ®Google Scholar
• S. Hussain, M. Wagner, D. Ly, and T.L. Delovitch, Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes, Immunol Res, 31: 177–188, 2005.
   Google Scholar
• L. Beaudoin, V. Laloux, J. Novak, B. Lucas, and A. Lehuen, NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells, Immunity, 17: 725–736, 2002.
   PubMed Web of Science ®Google Scholar
• J. Novak, L. Beaudoin, T. Griseri, and A. Lehuen, Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts, J. Immunol., 174: 1954–1961, 2005.
   PubMed Web of Science ®Google Scholar
• S. Sakaguchi, Naturally arising CD4 + regulatory t cells for immunologic self-tolerance and negative control of immune responses, Annu. Rev. Immunol., 22: 531–562, 2004.
   PubMed Web of Science ®Google Scholar
• M.S. Vincent, D.S. Leslie, J.E. Gumperz, X. Xiong, E.P. Grant, and M.B. Brenner, CD1-dependent dendritic cell instruction, Nat. Immunol., 3: 1163–1168, 2002.
   PubMed Web of Science ®Google Scholar
• G. Galli, S. Nuti, S. Tavarini, L. Galli-Stampino, C. De Lalla, G. Casorati, P. Dellabona, and S. Abrignani, CD1d-restricted help to B cells by human invariant natural killer T lymphocytes, J. Exp. Med., 197: 1051–1057, 2003.
   PubMed Web of Science ®Google Scholar
• M. Exley, J. Garcia, S.B. Wilson, F. Spada, D. Gerdes, S.M. Tahir, K.T. Patton, R.S. Blumberg, S. Porcelli, A. Chott, and S.P. Balk, CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes, Immunology, 100: 37–47, 2000.
   PubMed Web of Science ®Google Scholar
• L. Brossay, D. Jullien, S. Cardell, B.C. Sydora, N. Burdin, R.L. Modlin, and M. Kronenberg, Mouse CD1 is mainly expressed on hemopoietic-derived cells, J. Immunol., 159: 1216–1224, 1997.
   PubMed Web of Science ®Google Scholar
• D. Elewaut, L. Brossay, S.M. Santee, O.V. Naidenko, N. Burdin, H. De Winter, J. Matsuda, C.F. Ware, H. Cheroutre, and M. Kronenberg, Membrane lymphotoxin is required for the development of different subpopulations of NK T cells, J. Immunol., 165: 671–679, 2000.
   PubMed Web of Science ®Google Scholar
• B. Pasquier, L. Yin, M.C. Fondaneche, F. Relouzat, C. Bloch-Queyrat, N. Lambert, A. Fischer, G. de Saint-Basile, and S. Latour, Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product, J. Exp. Med., 201: 695–701, 2005.
   PubMed Web of Science ®Google Scholar
• K.E. Nichols, J. Hom, S.Y. Gong, A. Ganguly, C.S. Ma, J.L. Cannons, S.G. Tangye, P.L. Schwartzberg, G.A. Koretzky, and P.L. Stein, Regulation of NKT cell development by SAP, the protein defective in XLP, Nat. Med., 11: 340–345, 2005.
   PubMed Web of Science ®Google Scholar
• S. Read, S. Mauze, C. Asseman, A. Bean, R. Coffman, and F. Powrie, CD38 + CD45RB(low) CD4 + T cells: A population of T cells with immune regulatory activities in vitro, Eur. J. Immunol., 28: 3435–3447, 1998.
   PubMed Web of Science ®Google Scholar
• P. Bansal-Pakala, A.G. Jember, and M. Croft, Signaling through OX40 (CD134) breaks peripheral T-cell tolerance, Nat. Med., 7: 907–912, 2001.
   PubMed Web of Science ®Google Scholar
• H. Kitamura, K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, T. Kawano, M. Taniguchi, and T. Nishimura, The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells, J. Exp. Med., 189: 1121–1128, 1999.
   PubMed Web of Science ®Google Scholar
• S. Fujii, K. Shimizu, C. Smith, L. Bonifaz, and R.M. Steinman, Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein, J. Exp. Med., 198: 267–279, 2003.
   PubMed Web of Science ®Google Scholar
• S. Kojo, K. Seino, M. Harada, H. Watarai, H. Wakao, T. Uchida, T. Nakayama, and M. Taniguchi, Induction of regulatory properties in dendritic cells by Vα14 NKT cells, J. Immunol., 175: 3648–3655, 2005.
   PubMed Web of Science ®Google Scholar
• S. Oki, C. Tomi, T. Yamamura, and S. Miyake, Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo, Int. Immunol., 17: 1619–1629, 2005.
   PubMedGoogle Scholar
• L. Cederbom, H. Hall, and F. Ivars, CD4 + CD25 + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells, Eur. J. Immunol., 30: 1538–1543, 2000.
   PubMed Web of Science ®Google Scholar
• Y.G. Chen, C.M. Choisy-Rossi, T.M. Holl, H.D. Chapman, G.S. Besra, S.A. Porcelli, D.J. Shaffer, D. Roopenian, S.B. Wilson, and D.V. Serreze, Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes, J. Immunol., 174: 1196–1204, 2005.
   PubMed Web of Science ®Google Scholar
• E. Dahlen, G. Hedlund, and K. Dawe, Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation, J. Immunol., 164: 2444–2456, 2000.
   PubMed Web of Science ®Google Scholar
• M.L. Albert, M. Jegathesan, and R.B. Darnell, Dendritic cell maturation is required for the cross-tolerization of CD8 + T cells, Nat. Immunol., 2: 1010–1017, 2001.
   PubMed Web of Science ®Google Scholar
• K. Roelofs-Haarhuis, X. Wu, and E. Gleichmann, Oral tolerance to nickel requires CD4 + invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells, J. Immunol., 173: 1043–1050, 2004.
   PubMed Web of Science ®Google Scholar
• H.J. Kim, S.J. Hwang, B.K. Kim, K.C. Jung, and D.H. Chung, NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor β, and by clonally deleting antigen-specific T cells, Immunology, 118: 101–111, 2006.
   Google Scholar
• K.H. Sonoda, M. Exley, S. Snapper, S.P. Balk, and J. Stein-Streilein, CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site, J. Exp. Med., 190: 1215–1226, 1999.
   PubMed Web of Science ®Google Scholar
• K.H. Sonoda, D.E. Faunce, M. Taniguchi, M. Exley, S. Balk, and J. Stein-Streilein, NK T cell-derived IL-10 is essential for the differentiation of antigen- specific T regulatory cells in systemic tolerance, J. Immunol., 166: 42–50, 2001.
   PubMed Web of Science ®Google Scholar
• D.E. Faunce and J. Stein-Streilein, NKT cell-derived RANTES recruits APCs and CD8 + T cells to the spleen during the generation of regulatory T cells in tolerance, J. Immunol., 169: 31–38, 2002.
   PubMed Web of Science ®Google Scholar
• S. Jiang, D.S. Game, D. Davies, G. Lombardi, and R.I. Lechler, Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4 + CD25 + regulatory T cells? Eur. J. Immunol., 35: 1193–1200, 2005.
   Google Scholar
• R. Liu, A. La Cava, X.F. Bai, Y. Jee, M. Price, D.I. Campagnolo, P. Christadoss, T.L. Vollmer, L. Van Kaer, and F.D. Shi, Cooperation of invariant NKT cells and CD4 + CD25 + T regulatory cells in the prevention of autoimmune myasthenia, J. Immunol., 175: 7898–7904, 2005.
   PubMed Web of Science ®Google Scholar
• D. Ly, Q.-S. Mi, S. Hussain, and T. Delovitch, Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4 + CD25 + regulatory T cells, J. Immunol., 177: 3695–3704, 2006.
   PubMed Web of Science ®Google Scholar
• R.S. Liblau, F.S. Wong, L.T. Mars, and P. Santamaria, Autoreactive CD8 T cells in organ-specific autoimmunity: Emerging targets for therapeutic intervention, Immunity, 17: 1–6, 2002.
   PubMed Web of Science ®Google Scholar
• T. Griseri, L. Beaudoin, J. Novak, L.T. Mars, F. Lepault, R. Liblau, and A. Lehuen, Invariant NKT cells exacerbate type 1 diabetes induced by CD8 T cells, J. Immunol., 175: 2091–2101, 2005.
   Google Scholar
• R.T. Graser, T.P. DiLorenzo, F. Wang, G.J. Christianson, H.D. Chapman, D.C. Roopenian, S.G. Nathenson, and D.V. Serreze, Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions, J. Immunol., 164: 3913–3918, 2000.
   PubMed Web of Science ®Google Scholar
• M.A. Atkinson, M.A. Bowman, L. Campbell, B.L. Darrow, D.L. Kaufman, and N.K. Maclaren. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes, J. Clin. Invest., 94: 2125–2129, 1994.
   PubMed Web of Science ®Google Scholar
• B.O. Roep, H.S. Hiemstra, N.C. Schloot, R.R. De Vries, A. Chaudhuri, P.O. Behan, and J.W. Drijfhout. Molecular mimicry in type 1 diabetes: immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus, Ann. N. Y. Acad. Sci., 958: 163–165, 2002.
   PubMedGoogle Scholar
• J. Verdaguer, D. Schmidt, A. Amrani, B. Anderson, N. Averill, and P. Santamaria. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice, J. Exp. Med., 186: 1663–1676, 1997.
   PubMed Web of Science ®Google Scholar
• A.W. Jahng, I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, and V. Kumar, Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis, J. Exp. Med., 194: 1789–1799, 2001.
   PubMed Web of Science ®Google Scholar
• A.K. Singh, M.T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A.K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer, Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis, J. Exp. Med., 194: 1801–1811, 2001.
   PubMed Web of Science ®Google Scholar
• L.T. Mars, V. Laloux, K. Goude, S. Desbois, A. Saoudi, L. Van Kaer, H. Lassmann, A. Herbelin, A. Lehuen, and R.S. Liblau, Cutting edge: Vβ14-Jβ281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice, J. Immunol., 168: 6007–6011, 2002.
   PubMed Web of Science ®Google Scholar
• P.T. Lee, K. Benlagha, L. Teyton, and A. Bendelac, Distinct functional lineages of human V(α)24 natural killer T cells, J. Exp. Med., 195: 637–641, 2002.
   PubMed Web of Science ®Google Scholar
• J.E. Gumperz, S. Miyake, T. Yamamura, and M.B. Brenner, Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining, J. Exp. Med., 195: 625–636, 2002.
   PubMed Web of Science ®Google Scholar
• J.L. Matsuda, O.V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C.R. Wang, Y. Koezuka, and M. Kronenberg, Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers, J. Exp. Med., 192: 741–754, 2000.
   PubMed Web of Science ®Google Scholar
• K. Benlagha, A. Weiss, A. Beavis, L. Teyton, and A. Bendelac, In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers, J. Exp. Med., 191: 1895–1903, 2000.
   PubMed Web of Science ®Google Scholar
• M. Terabe, S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D.D. Donaldson, D.P. Carbone, W.E. Paul, and J.A. Berzofsky, NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway, Nat. Immunol., 1: 515–520, 2000.
   PubMed Web of Science ®Google Scholar
• M. Terabe, S. Matsui, J.M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, J.J. Letterio, W.E. Paul, and J.A. Berzofsky, Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence, J. Exp. Med., 198: 1741–1752, 2003.
   PubMed Web of Science ®Google Scholar
• N.Y. Crowe, J.M. Coquet, S.P. Berzins, K. Kyparissoudis, R. Keating, D.G. Pellicci, Y. Hayakawa, D.I. Godfrey, and M.J. Smyth, Differential antitumor immunity mediated by NKT cell subsets in vivo, J. Exp. Med., 202: 1279–1288, 2005.
   PubMed Web of Science ®Google Scholar
• V. Laloux, L. Beaudoin, C. Ronet, and A. Lehuen, Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes, J. Immunol., 168: 3251–3258, 2002.
   PubMedGoogle Scholar
• S. Cardell, S. Tangri, S. Chan, M. Kronenberg, C. Benoist, and D. Mathis, CD1-restricted CD4 + T cells in major histocompatibility complex class II-deficient mice, J. Exp. Med., 182: 993–1004, 1995.
   PubMed Web of Science ®Google Scholar
• M. Stenstrom, M. Skold, A. Ericsson, L. Beaudoin, S. Sidobre, M. Kronenberg, A. Lehuen, and S. Cardell, Surface receptors identify mouse NK1.1 + T cell subsets distinguished by function and T cell receptor type, Eur. J. Immunol., 34: 56–65, 2004.
   Google Scholar
• M. Skold, N.N. Faizunnessa, C.R. Wang, and S. Cardell, CD1d-specific NK1.1 + T cells with a transgenic variant TCR, J. Immunol., 165: 168–174, 2000.
   PubMedGoogle Scholar
• N. Duarte, M. Stenstrom, S. Campino, M.L. Bergman, M. Lundholm, D. Holmberg, and S.L. Cardell, Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells, J. Immunol., 173: 3112–3118, 2004.
   PubMed Web of Science ®Google Scholar
• S.B. Wilson, S.C. Kent, K.T. Patton, T. Orban, R.A. Jackson, M. Exley, S. Porcelli, D.A. Schatz, M.A. Atkinson, S.P. Balk, J.L. Strominger, and D.A. Hafler, Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes, Nature, 391: 177–181, 1998.
   PubMed Web of Science ®Google Scholar
• S.B. Wilson, S.C. Kent, H.F. Horton, A.A. Hill, P.L. Bollyky, D.A. Hafler, J.L. Strominger, and M.C. Byrne, Multiple differences in gene expression in regulatory Vα 24Jα Q T cells from identical twins discordant for type I diabetes, Proc. Natl. Acad. Sci. U. S. A., 97: 7411–7416, 2000.
   PubMed Web of Science ®Google Scholar
• A. Kukreja, G. Cost, J. Marker, C. Zhang, Z. Sun, K. Lin-Su, S. Ten, M. Sanz, M. Exley, B. Wilson, S. Porcelli, and N. Maclaren, Multiple immuno-regulatory defects in type-1 diabetes, J. Clin. Invest., 109: 131–140, 2002.
   PubMed Web of Science ®Google Scholar
• P.T. Lee, A. Putnam, K. Benlagha, L. Teyton, P.A. Gottlieb, and A. Bendelac, Testing the NKT cell hypothesis of human IDDM pathogenesis, J. Clin. Invest., 110: 793–800, 2002.
   PubMed Web of Science ®Google Scholar
• Y. Oikawa, A. Shimada, S. Yamada, Y. Motohashi, Y. Nakagawa, J. Irie, T. Maruyama, and T. Saruta, High frequency of vα24(+) vβ11(+) T-cells observed in type 1 diabetes, Diabetes Care, 25: 1818–1823, 2002.
   PubMed Web of Science ®Google Scholar
• S.P. Berzins, K. Kyparissoudis, D.G. Pellicci, K.J. Hammond, S. Sidobre, A. Baxter, M.J. Smyth, M. Kronenberg, and D.I. Godfrey, Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: Implications for human studies, Immunol. Cell Biol., 82: 247–252, 2004.
   PubMedGoogle Scholar
• S.C. Kent, Y. Chen, S.M. Clemmings, V. Viglietta, N.S. Kenyon, C. Ricordi, B. Hering, and D.A. Hafler, Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells, J. Immunol., 175: 4458–4464, 2005.
   PubMed Web of Science ®Google Scholar
• L.T. Mars, J. Novak, R.S. Liblau, and A. Lehuen, Therapeutic manipulation of iNKT cells in autoimmunity: Modes of action and potential risks, Trends Immunol., 25: 471–476, 2004.
   PubMed Web of Science ®Google Scholar
• O. Akbari, P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M.J. Grusby, R.H. DeKruyff, and D.T. Umetsu, Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity, Nat. Med., 9: 582–588, 2003.
   PubMed Web of Science ®Google Scholar
• M. Terabe and J.A.c. Berzofsky, Immunoregulatory T cells in tumor immunity, Curr. Opin. Immunol., 16: 157–162, 2004.
   PubMed Web of Science ®Google Scholar
• A. Jahng, I. Maricic, C. Aguilera, S. Cardell, R.C. Halder, and V. Kumar, Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide, J. Exp. Med., 199: 947–957, 2004.
   PubMed Web of Science ®Google Scholar
• E. Pal, T. Tabira, T. Kawano, M. Taniguchi, S. Miyake, and T. Yamamura, Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells, J. Immunol., 166: 662–668, 2001.
   PubMed Web of Science ®Google Scholar
• G. Giaccone, C.J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B.M. von Blomberg, R.J. Scheper, H.J. van der Vliet, A.J. van den Eertwegh, M. Roelvink, J. Beijnen, H. Zwierzina, and H.M. Pinedo, A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors, Clin. Cancer Res., 8: 3702–3709, 2002.
   PubMed Web of Science ®Google Scholar
• M. Nieda, M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D.J. Macfarlane, and A.J. Nicol, Therapeutic activation of Vα24 + Vβ11 + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity, Blood, 103: 383–389, 2004.
   PubMed Web of Science ®Google Scholar